Quick Answer
Aurinia Pharmaceuticals Inc. reported Total Revenue of $283.06 million for fiscal year 2025.
Aurinia Pharmaceuticals Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $283.06M +20.4% |
$235.13M +34.0% |
$175.51M +31.0% |
$134.03M +193.9% |
$45.60M -9.0% |
$50.12M +15660.4% |
| Revenue (ASC 606) | $283.06M +20.4% |
$235.13M +34.0% |
$175.51M +31.0% |
$134.03M +193.9% |
$45.60M -9.0% |
$50.12M +15660.4% |
| Net Income | $287.20M +4893.1% |
$5.75M +107.4% |
-$78.02M +27.9% |
-$108.18M +40.2% |
-$180.97M -76.2% |
-$102.68M -16.2% |
| Diluted EPS | $2.07 +5075.0% |
$0.04 +107.4% |
-$0.54 +28.9% |
-$0.76 +45.7% |
-$1.40 -60.9% |
-$0.87 +8.4% |
| Total Assets | $751.59M +36.5% |
$550.64M +0.5% |
$548.06M +16.4% |
$470.86M -13.3% |
$543.37M +17.2% |
$463.66M +43.0% |
| Cash and Equivalents | $80.16M -3.9% |
$83.40M +71.1% |
$48.76M -48.2% |
$94.09M -59.4% |
$231.64M -14.9% |
$272.35M -11.0% |
| Stockholders Equity | $581.33M +54.0% |
$377.48M -0.1% |
$377.95M -6.8% |
$405.44M -15.4% |
$479.09M +17.5% |
$407.75M +36.6% |
| R&D Expense | $32.51M +56.4% |
$20.79M -58.1% |
$49.64M +10.3% |
$44.99M -12.0% |
$51.14M +1.6% |
$50.33M -4.8% |
| Operating Income | $104.91M +2338.4% |
-$4.69M +94.9% |
-$91.69M +17.7% |
-$111.47M +38.3% |
-$180.74M -73.3% |
-$104.29M -14.7% |
| Shares Outstanding | 132.32M -6.1% |
140.88M -2.1% |
143.83M +1.1% |
142.27M +0.5% |
141.60M +11.8% |
126.70M +13.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $73.47M | +8.4% | +4.9% |
| Revenue (ASC 606) | September 30, 2025 | $73.47M | +8.4% | +4.9% |
| Net Income | September 30, 2025 | $31.55M | +119.9% | +46.7% |
| Diluted EPS | September 30, 2025 | $0.23 | +130.0% | +43.8% |
| Total Assets | September 30, 2025 | $527.53M | -4.0% | +5.0% |
| Cash and Equivalents | September 30, 2025 | $72.89M | +99.0% | +37.7% |
| Stockholders Equity | September 30, 2025 | $365.77M | -5.7% | +9.1% |
| R&D Expense | September 30, 2025 | $8.44M | +176.8% | +13.5% |
| Operating Income | September 30, 2025 | $29.75M | +153.2% | +48.1% |
| Shares Outstanding | September 30, 2025 | 131.84M | -7.9% | -0.6% |
- Aurinia Pharmaceuticals Inc. reported Total Revenue of $283.06 million for fiscal year 2025.
- Aurinia Pharmaceuticals Inc. showed an increase of +20.4% in Total Revenue compared to the prior fiscal year.
- Aurinia Pharmaceuticals Inc. reported Revenue (ASC 606) of $283.06 million for fiscal year 2025.
- Aurinia Pharmaceuticals Inc. showed an increase of +20.4% in Revenue (ASC 606) compared to the prior fiscal year.
- Aurinia Pharmaceuticals Inc. reported Net Income of $287.20 million for fiscal year 2025.
- Aurinia Pharmaceuticals Inc. showed an increase of +4893.1% in Net Income compared to the prior fiscal year.
- Aurinia Pharmaceuticals Inc. reported Diluted EPS of $2.07 per share for fiscal year 2025.
- Aurinia Pharmaceuticals Inc. showed an increase of +5075.0% in Diluted EPS compared to the prior fiscal year.
- Aurinia Pharmaceuticals Inc. reported Total Assets of $751.59 million for fiscal year 2025.
- Aurinia Pharmaceuticals Inc. showed an increase of +36.5% in Total Assets compared to the prior fiscal year.
- Aurinia Pharmaceuticals Inc. reported Cash and Equivalents of $80.16 million for fiscal year 2025.
- Aurinia Pharmaceuticals Inc. showed a decrease of -3.9% in Cash and Equivalents compared to the prior fiscal year.
- Aurinia Pharmaceuticals Inc. reported Stockholders Equity of $581.33 million for fiscal year 2025.
- Aurinia Pharmaceuticals Inc. showed an increase of +54.0% in Stockholders Equity compared to the prior fiscal year.
- Aurinia Pharmaceuticals Inc. reported R&D Expense of $32.51 million for fiscal year 2025.
- Aurinia Pharmaceuticals Inc. showed an increase of +56.4% in R&D Expense compared to the prior fiscal year.
- Aurinia Pharmaceuticals Inc. reported Operating Income of $104.91 million for fiscal year 2025.
- Aurinia Pharmaceuticals Inc. showed an increase of +2338.4% in Operating Income compared to the prior fiscal year.
- Aurinia Pharmaceuticals Inc. reported Shares Outstanding of 132.32 million shares for fiscal year 2025.
- Aurinia Pharmaceuticals Inc. showed a decrease of -6.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: